Help employers find you! Check out all the
MONTREAL, July 21, 2014 /PRNewswire/ - Milestone Pharmaceuticals Inc., a
cardiovascular drug development company, today announced the
appointment of Francis Plat, MD, FAHA, as Chief Medical Officer of the
Company. Dr. Plat is a board-certified cardiologist with extensive
experience in cardiovascular drug development. Most recently, Dr. Plat
was Vice President and Therapeutic Area Head, Atherosclerosis and
Cardiovascular at Merck Research Laboratories.
Dr. Plat is highly regarded for his 25 years of international clinical
research experience in the cardiovascular area having worked within a
number of global pharmaceutical companies including Merck Research
Laboratories, Daiichi-Sankyo, Novartis, and Bristol Myers Squibb. He
has been involved in the development, filing and repositioning of
numerous cardiovascular compounds (Zontivity, Brinavess, Effient, Azor,
Diovan, Tareg, Approvel, Avalide and edoxaban). He contributed to
several landmark cardiovascular clinical trials such as VALUE, VALIANT,
TRITON-TIMI 38, and ENGAGE AF-TIMI 48.
"I am highly enthused to join Milestone in its development of MSP-2017,
a promising product candidate, to alleviate acute episodes of
paroxysmal supraventricular tachycardia (PSVT)," said Dr. Plat.
"MSP-2017 is a nasal self-administered treatment-in-the-pocket that
will provide a paradigm shift in PSVT treatment by allowing patients to
get back to normal life within minutes after the resolution of an
episode without the need to go to an emergency room to receive an
"I am excited to welcome Dr. Plat to our team. Dr. Plat's appointment as
Milestone's Chief Medical Officer comes at a critical juncture for the
Company as we prepare for our Phase 2 trials," said Philippe Douville,
Chief Executive Officer of Milestone Pharmaceuticals. "Dr. Plat is the
perfect candidate for our development program given his extensive
cardiovascular drug development expertise developed during his career
in large pharmaceutical companies.
"I look forward to working closely with Dr. Plat as we move forward in
our phase 2 strategy. His wealth of CV Development leadership
experience will bring great value to Milestone Pharmaceuticals."
commented Dr. Philip Sager, FACC, FAHA, Chief Medical Advisor at
About Milestone Pharmaceuticals
Milestone is a drug development company developing novel small molecule
therapeutics based on clinically validated mechanisms for
cardiovascular diseases. Milestone's lead product is a novel and potent
short-acting calcium channel antagonist for the systemic treatment of
transient cardiovascular conditions such as supra ventricular
arrhythmias. The Company has assembled a world-class scientific
advisory board of key opinion leaders with significant cardiovascular
expertise in cardiology, regulatory affairs, and drug development. For
more information, please visit www.milestonepharma.com
SOURCE Milestone Pharmaceuticals Inc.